RxDoctor Payments Data

William Coyle, MD

Internal Medicine · Mc Murray, PANPI 1841271046

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 70 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$573
  • Pfizer$184
  • Novo Nordisk$129
  • Abbott$68
  • Lilly USA, LLC$48
  • AstraZeneca$34
  • plus $264 from 11 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,301 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$111,640
Medicare patients
225
Services billed
1,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin159$175,628
EliquisApixaban178$161,632
OzempicSemaglutide75$106,054
XareltoRivaroxaban64$66,338
RybelsusSemaglutide27$35,870
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog56$30,978
JanuviaSitagliptin Phosphate28$30,863
CreonLipase/Protease/Amylase15$27,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,601
Breo ElliptaFluticasone/Vilanterol42$22,390
TrulicityDulaglutide14$18,963
Tresiba Flextouch U-200Insulin Degludec18$17,128
MyrbetriqMirabegron33$14,137
JanumetSitagliptin Phos/Metformin Hcl13$12,149
MounjaroTirzepatide11$11,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$184$161,632178 claims
Novo NordiskOzempic, Rybelsus$129$141,924102 claims
Johnson & JohnsonXarelto$30$66,33864 claims
GSKTrelegy Ellipta, Breo Ellipta$26$44,99166 claims
AbbVieCreon, Synthroid$573$33,825170 claims
Lilly USA, LLCTrulicity, Mounjaro$48$30,05125 claims
Astellas Pharma US IncMyrbetriq$19$14,13733 claims
AstraZenecaBrilinta$34$9,87414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Mc Murray

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →